Suzhou, China

Leilei Zhao


 

Average Co-Inventor Count = 12.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovator Spotlight: Leilei Zhao and His Contributions to Cancer Treatment

Introduction: Leilei Zhao is an accomplished inventor based in Suzhou, China, recognized for his innovative contributions in the field of pharmaceuticals. With a focus on developing therapeutic agents for cancer treatment, Zhao holds a patent that underlines his expertise and dedication to improving health outcomes through scientific advances.

Latest Patents: Leilei Zhao is credited with a patent titled "Macrocyclic Spiroethers as Mcl-1 Inhibitors." This patent encompasses compounds represented by Formula (I-A) along with pharmaceutically acceptable salts and solvates thereof. The compounds are designed to treat conditions or disorders that are responsive to Mcl-1 inhibition, particularly targeting cancer.

Career Highlights: Throughout his career, Zhao has made significant strides in pharmaceutical research. He has worked with Ascentage Pharma (Suzhou) Co., Ltd., where he contributed to the development of innovative cancer therapies. Additionally, he has been associated with the University of Michigan, further solidifying his credentials as a prominent figure in the field of medicinal chemistry.

Collaborations: Leilei Zhao has collaborated effectively with talented professionals such as Jianyong Chen and Yunlong Zhou. These collaborations play an essential role in fostering innovative approaches to drug development and enhancing research quality.

Conclusion: Leilei Zhao's work exemplifies the impact of innovation in the medical field, particularly in the fight against cancer. His patented compounds offer promising therapeutic avenues and reflect the importance of continued research and development in improving patient care. As he progresses in his career, his contributions will undoubtedly yield significant benefits for the medical community and beyond.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…